(Q100152367)

English

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1

An instance of the biological reaction in Homo sapiens with Reactome ID (R-HSA-9665000)

In more languages

edit

Statements

1 reference

8 July 2022

Signaling by ERBB2 KD Mutants

1 reference

8 July 2022

1 reference

8 July 2022

https://identifiers.org/reactome:R-HSA-9665000

1 reference

8 July 2022

GRB2-1:SOS1 [cytosol]

1

1 reference

8 July 2022

p-6Y-ERBB2 KD mutants:EGF:p-6Y-EGFR [plasma membrane]

1

1 reference

8 July 2022

p-6Y-ERBB2 KD mutants:EGF:p-6Y-EGFR:GRB2:SOS1 [plasma membrane]

1

1 reference

8 July 2022

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation

1 reference

8 July 2022

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

8 July 2022

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

8 July 2022

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

1 reference

8 July 2022

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

1 reference

8 July 2022

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

1 reference

8 July 2022

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

1 reference

8 July 2022

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

1 reference

8 July 2022

Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity

1 reference

8 July 2022

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

1 reference

8 July 2022

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

8 July 2022

Identifiers

1 reference

8 July 2022

(Q100152367)

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)